Good article about Israel’s Collplant (reported here previously) and its technology that turns tobacco leaves into bio-ink for printing human organs. Collplant, together with United Therapeutics Corporation have already made lung parts and will now start working on printing replacement … Continue reading →

Israel’s CollPlant is partnering with US-based 3D Systems to spur breakthroughs in regenerative medicine. It brings together top 3D-printing technology with Collprint’s bioink technology for 3D bioprinting of tissues and organs. https://ir.collplant.com/press-releases/detail/83/3d-systems-and-collplant-biotechnologies-join-forces-to https://www.3dsystems.com/press-releases/3d-systems-and-collplant-biotechnologies-join-forces-accelerate-breakthroughs

Israel’s CollPlant has licensed US’s United Therapeutics to use CollPlant’s 3D bio-printing technology to manufacture lung transplants. The multi-million-dollar agreement can be expanded to print up to three additional organs. CollPlant will initially supply the necessary bio-ink https://ir.collplant.com/press-releases/detail/54/collplant-and-united-therapeutics-announce-global-licensing

Israel’s CollPlant (see here) is developing a proprietary rhCollagen-based formulations intended for use as bio-ink for the 3D printing of tissues and life savings organs.  It has now received grant approval (up to $1.2 million) of additional finance from the … Continue reading →

I’ve reported previously (see here) on Israel’s Collplant and its proprietary plant-based technology to produce rhCollagen (recombinant human collagen). CollPlant has just opened a new facility in Rehovot, for producing rhCollagen to make tissue repair products and 3D printing of … Continue reading →

I reported previously (Jun 5) that Israel’s Collplant was developing a bio-ink that could 3D print tissues and organs. Collplant has now setup a division to produce the ink, which could eventually be the answer for patients desperately waiting for … Continue reading →

Israel’s CollPlant has been awarded the EU CE Mark for VergenixSTR, a soft tissue repair matrix for the treatment of tendinopathy (tendon injury or disease and associated pain).  VergenixSTR is based on CollPlant’s proprietary plant-based collagen technology. http://www.globes.co.il/en/article-collplant-awarded-eu-ce-mark-for-tendinopathy-treatment-1001156788

Israel’s Collplant has reported positive results of trials of its Vergenix STR treatment for inflammation of the elbow tendon – commonly referred to as tennis elbow.  Most of the 40 patients reported less pain and disability – far better than … Continue reading →